This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

ChinaBio® Partnering Forum Content

Prepare for your partnering experience with the most accurate and up-to-date information on China life sciences.

State of China Life Science: 2021

Back on Track - VC, Partnering and IPOs Exploding

Download this exclusive report by ChinaBio® to review all of the financing and partnering trends in this vibrant sector.

Report highlights:

  • VC/PE Fundraising: $56.1 billion; 2.3 times 2019; 
  • VC/PE Investments: $28.5 billion; 2.0 times 2019; 
  • IPOs: $23.3 billion; 2.9 times 2019; 
  • Partnering: $30.5 billion; 1.7 times 2019


Bigger deals, higher valuations, greater access to capital

The biopharma industry continues to fare well in the global capital markets, providing companies with opportunities to raise impressive funding rounds and launch impressive IPOs. Whether in Shanghai, New York or Hong Kong, the sector is hot with record-breaking IPOs, including two of the world’s largest. The CEOs of RemeGen, JW Therapeutics and I-Mab share their insights on navigating the road to success.

Looking ahead – what to expect in the new world order

Despite Covid-19’s devastating impact on lives and economies around the world, investments and deals in the biopharma sector were robust, especially in China. Companies seeking to launch or expand in China are strategically placing their bets to maximize growth opportunities. Executives from ChinaBio Group. Bayer Healthcare, Qiming Venture Partners, Decheng Capital and ATLATL Innovation Center share their forecasts for 2021.

Johnson & Johnson’s approach to external innovation

William N. Hait, MD, PhD, Global Head at Johnson & Johnson External Innovation, gives an exclusive interview to Lucie Ellis, Executive Editor of In Vivo, Pharma Intelligence. Watch to learn how partners complement J&J innovation, how digital health, artificial intelligence, and machine learning fit into their strategy, and the details regarding the company’s presence in China.


Top Biotech Deals in China

Discover the deals transforming China biotech. More than $12 billion in biopharma financing, alliances, IPOs, and new funds have been generated so far this year in China. Learn the details of these deals when you read this new infographic.


J&J’s multi-pronged approach to life science innovation, partnerships, and advanced technologies

Dr. Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific, and Dr. Sharon Chan, Head of JLABS @ Shanghai discuss its support of startups, interests in diverse disease areas, the importance of collaborations and much more in this exclusive interview with EBD Group.


Roche’s approach to drug discovery, innovation and meeting patients' needs

In an exclusive interview James Sabry, Global Head of Roche Pharma Partnering, discusses Roche’s approach to discovering scientific breakthroughs, accelerating innovative research, collaborating with stakeholders, and meeting unmet medical needs in China and around the world.


China's Challenges in the Wake of COVID-19

Gain a rare peek into the policies behind the vaccines race in China and the impact COVID-19 has had on its pharmaceutical supply chains, plus much more in this exclusive article pack from Pharma Intelligence.